Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Matthew D. Overturf, Jordan C. Anderson, Zacharias Pandelides, Lindsay Beyger & Douglas A. Holdway. (2015) Pharmaceuticals and personal care products: A critical review of the impacts on fish reproduction. Critical Reviews in Toxicology 45:6, pages 469-491.
Read now
Read now
Gian Benedetto Melis, Marisa Orrù, Maria Francesca Marotto, Monica Pilloni, Mariagrazia Perseu, Stefano Lello & Anna Maria Paoletti. (2011) Use of oral contraceptives in the management of acne. Open Access Journal of Contraception 2, pages 151-159.
Read now
Read now
Regine Sitruk-Ware, Ronald Bossemeyer & Phillipe Bouchard. (2007) Preclinical and clinical properties of trimegestone: A potent and selective progestin. Gynecological Endocrinology 23:6, pages 310-319.
Read now
Read now
H Kuhl. (2005) Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 8:sup1, pages 3-63.
Read now
Read now
PR Koninckx, D Spielmann & The Trimegestone 302 Study Group. (2005) A comparative 2-year study of the effects of sequential regimens of 1 mg 17β-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women. Gynecological Endocrinology 21:2, pages 82-89.
Read now
Read now
M Gambacciani, D Spielmann, AR Genazzani & The Trimegestone 301 Study Group. (2005) Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17β-estradiol and trimegestone versus two regimens containing 1 or 2 mg 17β-estradiol and norethisterone acetate. Gynecological Endocrinology 21:2, pages 65-73.
Read now
Read now
B Pornel, D Spielmann & The Trimegestone 302 Study Group. (2005) A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17β-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a 2-year period. Gynecological Endocrinology 21:2, pages 74-81.
Read now
Read now
R. Sitruk-Ware. (2005) Pharmacology of different progestogens: the special case of drospirenone. Climacteric 8:sup3, pages 4-12.
Read now
Read now
P. Bouchard, F. De Cicco-Nardone, D. Spielmann, N. Garcea & The Trimegestone 301 Study Group. (2005) Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17beta-estradiol/trimegestone versus 1 or 2 mg 17beta-estradiol/norethisterone acetate in postmenopausal women. Gynecological Endocrinology 21:3, pages 142-148.
Read now
Read now
F Al-Azzawi, M Wahab, S Sami, AJ Proudler, J Thompson & J Stevenson. (2004) Randomized trial of effects of estradiol in combination with either norethisterone acetate or trimegestone on lipids and lipoproteins in postmenopausal women. Climacteric 7:3, pages 292-300.
Read now
Read now
R Sitruk-Ware, F Husmann, JHH Thijssen, SO Skouby, F Fruzzetti, J Hanker, J Huber & R Druckmann. (2004) Role of progestins with partial antiandrogenic effects. Climacteric 7:3, pages 238-254.
Read now
Read now
Puwen Zhang, Andrew Fensome, Jay Wrobel, Richard Winneker & Zhiming Zhang. (2003) Non-steroidal progesterone receptor modulators. Expert Opinion on Therapeutic Patents 13:12, pages 1839-1847.
Read now
Read now
J. H. J. M. Meuwissen, L. Beijers-De Bie, T. Vihtamaki, R. Tuimala, N. Siseles, C. Magaril, H. S. The, P. W. H. Houben, M. Murga, D. Spielmann & T. J. de Villiers. (2002) Assessment of the metabolic tolerance in postmenopausal women over a 1-year period of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone. Gynecological Endocrinology 16:2, pages 155-162.
Read now
Read now
Farook Al-Azzawi & May Wahab. (2001) Trimegestone: expanding therapeutic choices for the treatment of the menopause. Expert Opinion on Investigational Drugs 10:9, pages 1737-1744.
Read now
Read now
M. Oettel, W. Elger, T. Gräser, C. Holz, P. Lähteenmäki & V. Patchev. (2001) What is past is prologue: estrogen/progestin replacement tomorrow. Gynecological Endocrinology 15:sup4, pages 68-90.
Read now
Read now
J. H. J. M. Meuwissen, L. Beijers-De Bie, T. Vihtamaki, R. Tuimala, N. Siseles, C. Magaril, H. S. The, P. W. H. Houben, M. Murga, D. Spielmann & T. J. De Villiers. (2001) A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone. Gynecological Endocrinology 15:5, pages 349-358.
Read now
Read now
L. Lepescheux, J. Secchi, M. Gaillard-Kelly & P. Miller. (2001) Effects of 17β-estradiol and trimegestone alone ,and in combination ,on the bone and uterus of ovariectomized rats. Gynecological Endocrinology 15:4, pages 312-320.
Read now
Read now
Y. Bouali, M. Gaillard-Kelly & P. J. Marie. (2001) Effect of trimegestone alone or in combination with estradiol on bone mass and bone turnover in an adult rat model of osteopenia. Gynecological Endocrinology 15:1, pages 48-55.
Read now
Read now
F. Al-Azzawi, M. Wahab, J. Thompson, B. Pornel, E. Hirvonen, O. Ylikorkala, M. J. van der Mooren, J. Dillon & C. Magaril. (2001) Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate. Climacteric 4:4, pages 343-354.
Read now
Read now
Articles from other publishers (46)
Jenna C. Stone & Maureen J. MacDonald. (2023) The impacts of endogenous progesterone and exogenous progestin on vascular endothelial cell, and smooth muscle cell function: A narrative review. Vascular Pharmacology 152, pages 107209.
Crossref
Crossref
Xiao-Bing Long, Wen-Jun Shi, Chong-Rui Yao, Si-Ying Li, Jin-Ge Zhang, Zhi-Jie Lu, Dong-Dong Ma, Yu-Xia Jiang & Guang-Guo Ying. (2023) Norethindrone suppress the germ cell development via androgen receptor resulting in male bias. Aquatic Toxicology 261, pages 106604.
Crossref
Crossref
Ana R. Gomes, Ana S. Pires, Fernanda M. F. Roleira & Elisiário J. Tavares-da-Silva. (2023) The Structural Diversity and Biological Activity of Steroid Oximes. Molecules 28:4, pages 1690.
Crossref
Crossref
Ramune Griksiene, Rasa Monciunskaite & Osvaldas Ruksenas. (2022) What is there to know about the effects of progestins on the human brain and cognition?. Frontiers in Neuroendocrinology 67, pages 101032.
Crossref
Crossref
Wen-Jun Shi, Dong-Dong Ma, Gui-Zhen Fang, Jin-Ge Zhang, Guo-Yong Huang, Lingtian Xie, Hong-Xing Chen, Li-Ping Hou & Guang-Guo Ying. (2021) Levonorgestrel and dydrogesterone affect sex determination via different pathways in zebrafish. Aquatic Toxicology 240, pages 105972.
Crossref
Crossref
Nicole L. Moore, Adrienne R. Hanson, Esmaeil Ebrahimie, Theresa E. Hickey & Wayne D. Tilley. (2020) Anti-proliferative transcriptional effects of medroxyprogesterone acetate in estrogen receptor positive breast cancer cells are predominantly mediated by the progesterone receptor. The Journal of Steroid Biochemistry and Molecular Biology 199, pages 105548.
Crossref
Crossref
Renate Louw-du Toit, Janet P. Hapgood & Donita Africander. (2020) A direct comparison of the transcriptional activities of progestins used in contraception and menopausal hormone therapy via the mineralocorticoid receptor. Biochemical and Biophysical Research Communications 526:2, pages 466-471.
Crossref
Crossref
Nirk E. Quispe Calla, Rodolfo D. Vicetti Miguel, Angelo R. Torres, Wayne Trout, Janelle M. Gabriel, Alissa M. Hatfield, Kristen M. Aceves, Jesse J. Kwiek, Balveen Kaur & Thomas L. Cherpes. (2020) Norethisterone Enanthate Increases Mouse Susceptibility to Genital Infection with Herpes Simplex Virus Type 2 and HIV Type 1. ImmunoHorizons 4:2, pages 72-81.
Crossref
Crossref
Craig S. Atwood & Samuel F. Ekstein. (2019) Human versus non-human sex steroid use in hormone replacement therapies part 1: Preclinical data. Molecular and Cellular Endocrinology 480, pages 12-35.
Crossref
Crossref
Frank Z. Stanczyk, Brett W. Mathews & Victoria K. Cortessis. (2017) Does the type of progestin influence the production of clotting factors?. Contraception 95:2, pages 113-116.
Crossref
Crossref
Michael A. Kirby, Anne C. Heuerman, Melisa Custer, Abigail E. Dobyns, Ryan Strilaeff, Kathleen N. Stutz, Jaclyn Cooperrider, Joseph G. Elsissy & Steven M. Yellon. (2016) Progesterone Receptor–Mediated Actions Regulate Remodeling of the Cervix in Preparation for Preterm Parturition. Reproductive Sciences 23:11, pages 1473-1483.
Crossref
Crossref
Adrienn Csányi, Judit Bóta, George Falkay, Robert Gáspár & Eszter Ducza. (2016) The Effects of Female Sexual Hormones on the Expression of Aquaporin 5 in the Late-Pregnant Rat Uterus. International Journal of Molecular Sciences 17:8, pages 1300.
Crossref
Crossref
Silvia Giatti, Roberto Cosimo Melcangi & Marzia Pesaresi. (2016) The other side of progestins: effects in the brain. Journal of Molecular Endocrinology 57:2, pages R109-R126.
Crossref
Crossref
Johan Svensson, Arshi Mustafa, Jerker Fick, Monika Schmitz & Björn Brunström. (2016) Developmental exposure to progestins causes male bias and precocious puberty in zebrafish (Danio rerio). Aquatic Toxicology 177, pages 316-323.
Crossref
Crossref
Vimal Kumar, Andrew C. JohnsonAchim Trubiroha, Jitka Tumová, Masaru Ihara, Roman Grabic, Werner Kloas, Hiroaki Tanaka & Hana Kocour Kroupová. (2015) The Challenge Presented by Progestins in Ecotoxicological Research: A Critical Review. Environmental Science & Technology 49:5, pages 2625-2638.
Crossref
Crossref
Lene H. Petersen, David Hala, Dennis Carty, Mark Cantu, Dalma Martinović & Duane B. Huggett. (2015)
Effects of progesterone and norethindrone on female fathead minnow (
Pimephales promelas
) steroidogenesis
. Environmental Toxicology and Chemistry 34:2, pages 379-390.
Crossref
Crossref
A.O. Mueck, X. Ruan, H. Seeger, T. Fehm & H. Neubauer. (2014) Genomic and non-genomic actions of progestogens in the breast. The Journal of Steroid Biochemistry and Molecular Biology 142, pages 62-67.
Crossref
Crossref
J.P. Hapgood, D. Africander, R. Louw, R.M. Ray & J.M. Rohwer. (2014) Potency of progestogens used in hormonal therapy: Toward understanding differential actions. The Journal of Steroid Biochemistry and Molecular Biology 142, pages 39-47.
Crossref
Crossref
Frank Z. Stanczyk & David F. Archer. (2014) Gestodene: A review of its pharmacology, potency and tolerability in combined contraceptive preparations. Contraception 89:4, pages 242-252.
Crossref
Crossref
Frank Z. StanczykJanet P. Hapgood, Sharon Winer & Daniel R. MishellJr.Jr.. (2013) Progestogens Used in Postmenopausal Hormone Therapy: Differences in Their Pharmacological Properties, Intracellular Actions, and Clinical Effects. Endocrine Reviews 34:2, pages 171-208.
Crossref
Crossref
Donita Africander, Renate Louw & Janet P. Hapgood. (2013) Investigating the anti-mineralocorticoid properties of synthetic progestins used in hormone therapy. Biochemical and Biophysical Research Communications 433:3, pages 305-310.
Crossref
Crossref
Johan Svensson, Jerker Fick, Ingvar Brandt & Björn Brunström. (2013)
The Synthetic Progestin Levonorgestrel Is a Potent Androgen in the Three-Spined Stickleback (
Gasterosteus aculeatus
)
. Environmental Science & Technology 47:4, pages 2043-2051.
Crossref
Crossref
Nicole L. Moore, Theresa E. Hickey, Lisa M. Butler & Wayne D. Tilley. (2012) Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells. Molecular and Cellular Endocrinology 357:1-2, pages 60-70.
Crossref
Crossref
Donita Africander, Renate Louw, Nicolette Verhoog, Dewald Noeth & Janet P. Hapgood. (2011) Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract. Contraception 84:4, pages 423-435.
Crossref
Crossref
Katie E. Hadley, Ann Louw & Janet P. Hapgood. (2011) Differential nuclear localisation and promoter occupancy play a role in glucocorticoid receptor ligand-specific transcriptional responses. Steroids 76:10-11, pages 1176-1184.
Crossref
Crossref
Donita Africander, Nicolette Verhoog & Janet P. Hapgood. (2011) Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids 76:7, pages 636-652.
Crossref
Crossref
Regine Sitruk-Ware & Anita Nath. (2010) The use of newer progestins for contraception. Contraception 82:5, pages 410-417.
Crossref
Crossref
H. Rozenbaum. (2009) Progestérone et progestatifs de synthèse. EMC - Gynécologie 4:2, pages 1-21.
Crossref
Crossref
Regine Sitruk-Ware. (2008) Reprint of Pharmacological profile of progestins. Maturitas 61:1-2, pages 151-157.
Crossref
Crossref
Franca Fruzzetti, Veronica Lazzarini, Cabiria Ricci, Barbara Quirici, Marco Gambacciani, Anna Maria Paoletti & Andrea Riccardo Genazzani. (2007) Effect of an oral contraceptive containing 30 μg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Contraception 76:3, pages 190-194.
Crossref
Crossref
Franca Fruzzetti, Stefano Lello, Veronica Lazzarini, Stefania Fratta, Marisa Orrù, Roberto Sorge, Luigi Minerba, Cabiria Ricci, Andrea Riccardo Genazzani, Gian Benedetto Melis & Anna Maria Paoletti. (2007) The oral contraceptive containing 30 μg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study. Contraception 75:3, pages 199-203.
Crossref
Crossref
Marianne CanonicoEmmanuel OgerGeneviève Plu-BureauJacqueline ConardGuy MeyerHervé LévesqueNathalie TrillotMarie-Thérèse BarrellierDenis WahlJoseph EmmerichPierre-Yves Scarabin. (2007) Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women. Circulation 115:7, pages 840-845.
Crossref
Crossref
May WahabFarook Al-Azzawi. (2016) Current State of Hormone Replacement Therapy: The Case for Using Trimegestone. Women's Health 2:4, pages 539-550.
Crossref
Crossref
Farook Al-Azzawi, John Thompson & John Stevenson. (2006) Which progestogen is more likely to increase the risk of fatal myocardial infarction: A combination of epidemiological and trial evidence. Maturitas 54:2, pages 154-163.
Crossref
Crossref
Regine Sitruk-Ware. (2006) New progestagens for contraceptive use. Human Reproduction Update 12:2, pages 169-178.
Crossref
Crossref
M. Birkhäuser. (2006) Klinische Bedeutung von gestagenen PartialwirkungenClinical significance of partial gestagen effects. Gynäkologische Endokrinologie 4:1, pages 52-64.
Crossref
Crossref
Rebecca A. Shirk, Zhiming Zhang & Richard C. Winneker. (2005) Differential effects of estrogens and progestins on the anticoagulant tissue factor pathway inhibitor in the rat. The Journal of Steroid Biochemistry and Molecular Biology 94:4, pages 361-368.
Crossref
Crossref
Regine Sitruk-Ware. (2004) Pharmacological profile of progestins. Maturitas 47:4, pages 277-283.
Crossref
Crossref
Richard C Winneker, Daniel Bitran & Zhiming Zhang. (2003) The preclinical biology of a new potent and selective progestin: trimegestone. Steroids 68:10-13, pages 915-920.
Crossref
Crossref
Regine Sitruk-Ware, Margaret Small, Narender Kumar, Yun-Yen Tsong, Kalyan Sundaram & Theodore Jackanicz. (2003) Nestorone®: clinical applications for contraception and HRT. Steroids 68:10-13, pages 907-913.
Crossref
Crossref
Lin Zhi, Christopher M. Tegley, Barbara Pio, James P. Edwards, Mehrnouch Motamedi, Todd K. Jones, Keith B. Marschke, Dale E. Mais, Boris Risek & William T. Schrader. (2003)
5-Benzylidene-1,2-dihydrochromeno[3,4-
f
]quinolines as Selective Progesterone Receptor Modulators
. Journal of Medicinal Chemistry 46:19, pages 4104-4112.
Crossref
Crossref
Sam Rowlands. (2003) Newer progestogens. Journal of Family Planning and Reproductive Health Care 29:1, pages 13-16.
Crossref
Crossref
Puwen Zhang, Eugene A. Terefenko, Andrew Fensome, Jay Wrobel, Richard Winneker, Scott Lundeen, Keith B. Marschke & Zhiming Zhang. (2002)
6-Aryl-1,4-dihydro-benzo[
d
][1,3]oxazin- 2-ones: A Novel Class of Potent, Selective, and Orally Active Nonsteroidal Progesterone Receptor Antagonists
. Journal of Medicinal Chemistry 45:20, pages 4379-4382.
Crossref
Crossref
Patrick Bernardelli, Bernard Gaudillière & Fabrice Vergne. 2002. Annual Reports in Medicinal Chemistry Volume 37. Annual Reports in Medicinal Chemistry Volume 37
257
277
.
Scott G Lundeen, Zhiming Zhang, Yuan Zhu, Jeffrey M Carver & Richard C Winneker. (2001) Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone. The Journal of Steroid Biochemistry and Molecular Biology 78:2, pages 137-143.
Crossref
Crossref
May Wahab, John Thompson & Farook Al-Azzawi. (2000) The effect of submucous fibroids on the dose-dependent modulation of uterine bleeding by trimegestone in postmenopausal women treated with hormone replacement therapy. BJOG: An International Journal of Obstetrics and Gynaecology 107:3, pages 329-334.
Crossref
Crossref